Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis
| Autor: | Jiajia Liu, Jie Shi, Yong-Bo Zheng, Li-Juan Bai, Jin-Qiao Li, Yanping Bao, Ying Han, Lin Lu, Xi-Mei Zhu, Le Shi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty medicine.drug_class Cognitive Neuroscience media_common.quotation_subject Disease Cholinergic Antagonists Behavioral Neuroscience Alzheimer Disease Risk Factors mental disorders Anticholinergic medicine Humans Dementia Risk factor Intensive care medicine Anticholinergic Drugs media_common business.industry Public health medicine.disease Neuropsychology and Physiological Psychology Pharmaceutical Preparations Meta-analysis business |
| Zdroj: | Neuroscience & Biobehavioral Reviews. 127:296-306 |
| ISSN: | 0149-7634 |
| Popis: | Dementia is one of the greatest global challenges for public health; however, the relationship between anticholinergic drugs and dementia remains unclear. The aim of the present study was to perform a systematic review and meta-analysis of the predictive roles of anticholinergic drugs in dementia risk. After pooling fourteen longitudinal and case-control studies with a total of 1,564,181 subjects, anticholinergic drug use was associated with an increased risk of all-cause dementia and Alzheimer's disease. Both low and high anticholinergic drug burdens were associated with dementia. Moreover, there was a dose-dependent relationship between anticholinergic drugs and risk of dementia. With respect to the categories of anticholinergic drugs, antiparkinson, urological drugs, and antidepressants increased the risk for dementia; however, cardiovascular and gastrointestinal drugs played potentially protective roles. These findings underscore the importance of anticholinergic drugs as a potential modifiable risk factor for dementia and provide treatment priorities to optimize dementia prevention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect